A Study of SGN-CD228A in Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Cutaneous Melanoma|Pleural Mesothelioma|HER2 Negative Breast Neoplasms|Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Adenocarcinoma
Interventions: DRUG: SGN-CD228A
Sponsor: Seagen Inc.